<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Abstract In 1976 the French-American-British <z:hpo ids='HP_0001909'>leukemia</z:hpo> working group (FAB) proposed the first definitions of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, namely <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Subsequent publications resulted in additional subgroups that had prognostic significance </plain></SENT>
<SENT sid="2" pm="."><plain>The incorporation of the subgroupings by the W.H.O. and additional fine tuning of the degrees of morphologic <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and the % of blasts has enhanced the classification </plain></SENT>
<SENT sid="3" pm="."><plain>Several prognostic scoring systems have added degrees of cytopenia, cytogenetic aberrations and molecular genetic mutations that allow care providers to subdivide cases into lower, intermediate and higher grade categories </plain></SENT>
</text></document>